Orphazyme burned through millions of dollars in futile fight for success
![Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14117309.ece/ALTERNATES/schema-16_9/20210618-130534-5-4032x2263ma%2520(2).jpg)
Despite its best efforts, biotech firm Orphazyme never managed to make an approved drug out of its candidate arimoclomol. This was despite the firm spending billions of kroner on the candidate.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Orphazyme reports USD 90m deficit for 2021
For subscribers
Orphazyme CEO on sale: "It’s sad, but we tried everything"
For subscribers
Orphazyme is now officially in American hands
For subscribers